Lifeward (NASDAQ: LFWD) appoints Keith D. Rose, M.D. as new CMO

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Lifeward Ltd. appointed Keith D. Rose, M.D. as its Chief Medical Officer, effective May 1, 2026. He has served in several senior medical affairs roles at the company since March 2023, most recently as Vice President, Medical Affairs, Medical Director – Neurosciences.

Before joining Lifeward, Dr. Rose held medical leadership positions at Biocodex, Novocure, Ipsen, Jazz Pharmaceuticals and Indivior. He earned his medical degree with distinction from The George Washington University and completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

CMO effective date: May 1, 2026 Announcement date: May 18, 2026 Residency duration: Five-year residency

3 metrics

CMO effective date May 1, 2026 Effective date of Keith D. Rose, M.D. as Chief Medical Officer

Announcement date May 18, 2026 Date Lifeward announced the CMO appointment

Residency duration Five-year residency Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine

Key Terms

Chief Medical Officer, Emerging growth company, Medical Affairs, Neurosciences

4 terms

Chief Medical Officer financial

"announced the appointment of Keith D. Rose, M.D. as Chief Medical Officer of the Company"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Medical Affairs technical

"National Medical Director, Medical Affairs – Neurosciences and Medical Director, Consultant, Medical Affairs – Neurosciences"

Medical affairs is the team in a healthcare company that translates clinical science into clear, accurate information for doctors, regulators and patients, and manages post-approval safety and education. Think of it as a trusted translator and guide that helps ensure a drug or device is used correctly, understood by the medical community, and monitored after launch — factors that affect regulatory outcomes, adoption and long-term commercial value for investors.

Neurosciences technical

"National Medical Director, Medical Affairs – Neurosciences and Medical Director, Consultant, Medical Affairs – Neurosciences"

The neurosciences are the collection of scientific and medical fields that study the brain, spinal cord and nerves to understand how they produce thoughts, sensations and movement. For investors, breakthroughs or setbacks in this area affect the value of companies developing drugs, devices or tests for neurological conditions because progress can mean large markets, long development timelines, high regulatory risk and potentially lasting competitive advantage—think of it as engineering solutions for the body’s most complex computer.

Understanding 8-K Material Events →

05/19/2026 - 08:37 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2026

Lifeward Ltd.

(Exact name of registrant as specified in its charter)

Israel		001-36612		Not applicable
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2 Cabot Rd., Hudson, MA		01749
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +508.251.1154

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Exchange Act

Title of each class		Trading symbol		Name of exchange on which registered
Ordinary Shares, no par value		LFWD		Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

On May 18, 2026, Lifeward Ltd. (the “Company”) announced the appointment of Keith D. Rose, M.D. as Chief Medical Officer of the Company, effective as of May 1, 2026.

Prior to this role, Dr. Rose served in positions of increasing responsibility at the Company since March 2023, including as National Medical Director, Medical Affairs – Neurosciences and Medical Director, Consultant, Medical Affairs – Neurosciences, and most recently as Vice President, Medical Affairs, Medical Director – Neurosciences. Before joining the Company, Dr. Rose served as the Medical Director, Medical Affairs at Biocodex, Inc. from November 2021 to June 2023 and Lead Clinical Research Scientist/Regional Manager in Oncology at Novocure, Inc. (NASDAQ: NVCR) from June 2020 to November 2021. Prior to those roles, Dr. Rose held various senior medical affairs and clinical leadership positions at Biocodex, Ipsen, Biosciences, Inc., Jazz Pharmaceuticals plc and Indivior PLC. Dr. Rose earned his Doctor of Medicine degree with distinction from The George Washington University School of Medicine and completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Lifeward Ltd.

Dated: May 19, 2026	By:	/s/ Almog Adar
	Name:	Almog Adar
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What executive change did Lifeward (LFWD) announce on May 18, 2026?

Lifeward announced the appointment of Keith D. Rose, M.D. as Chief Medical Officer, effective May 1, 2026. He previously held senior medical affairs roles at Lifeward since March 2023 and brings extensive clinical and industry experience in neurosciences and medical affairs leadership.

What is Keith D. Rose, M.D.’s background before becoming Lifeward (LFWD) Chief Medical Officer?

Before becoming Chief Medical Officer, Dr. Rose served as Vice President, Medical Affairs, Medical Director – Neurosciences at Lifeward. Earlier roles included senior medical affairs and clinical positions at Biocodex, Novocure, Ipsen, Jazz Pharmaceuticals and Indivior, providing broad experience across multiple therapeutic areas.

When did Keith D. Rose, M.D. officially assume the Chief Medical Officer role at Lifeward (LFWD)?

Keith D. Rose, M.D. officially assumed the Chief Medical Officer role effective May 1, 2026. The company disclosed the appointment on May 18, 2026, highlighting his prior internal leadership roles in medical affairs and his broader pharmaceutical and clinical research experience.

What are some of Keith D. Rose, M.D.’s prior positions within Lifeward (LFWD)?

Within Lifeward, Dr. Rose previously served as National Medical Director, Medical Affairs – Neurosciences, Medical Director, Consultant, Medical Affairs – Neurosciences, and most recently Vice President, Medical Affairs, Medical Director – Neurosciences, demonstrating a progression of responsibilities in the company’s medical leadership.

What education and training does Lifeward (LFWD) Chief Medical Officer Keith D. Rose, M.D. have?

Dr. Rose earned his Doctor of Medicine degree with distinction from The George Washington University School of Medicine. He completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine, giving him combined expertise in rehabilitation and pediatric care.

Which other companies did Lifeward (LFWD) CMO Keith D. Rose, M.D. work for previously?

Before Lifeward, Dr. Rose worked at Biocodex, Inc. as Medical Director, Medical Affairs and at Novocure, Inc. as Lead Clinical Research Scientist/Regional Manager in Oncology. He also held senior medical affairs and clinical leadership roles at Ipsen, Jazz Pharmaceuticals and Indivior.

Filing Exhibits & Attachments

3 documents